CorFlow Therapeutics Appoints Medtronic Veteran Chris O’Connell as Chairman Ahead of IPO

CorFlow Therapeutics Appoints Chris O’Connell as Chairman of the Board, Replacing Rick Geoffrion. Rick Geoffrion Will Continue to Serve as a Director of the Company.Chris O’Connell is a highly respected senior executive with extensive experience as a board member and advisor in the medical device, life sciences, and global healthcare industries.

Chris O’Connell Resume

Chris's career began at Medtronic (1994-2015), during his 21-year tenure,Medtronic is in a period of rapid expansion. He has held key positions across multiple business units and functional departments, including senior leadership roles in the Cardiovascular and Diabetes divisions, before being promoted to Executive Vice President and President of the Restorative Therapies Group, serving as a member of Medtronic’s Executive Committee for nine years.

Thereafter, Chris served as Chief Executive Officer and President of Waters Corporation (2015-2021), leading the company to achieve strong business growth and a rise in stock price over a term of more than five years.

Currently,Chris serves as an independent director for several innovative growth companies in the medical device, life sciences, and diagnostics fields, and is involved in the work of multiple non-profit organizations.

Company Evaluation

"At this critical stage of the company's development, Chris has brought exceptional strategic vision and operational wisdom to CorFlow. His experience in corporate management within the medical technology sector, along with his boardroom expertise and multiple buy-side M&A transactions, has given him a deep understanding of the industry’s highest standards across all functions. On behalf of the Board of Directors, shareholders, and all employees, we are thrilled to welcome him."

---Paul Mead  CEO of CorFlow Therapeutics

CorFlow is currently working towards an ambitious goal for its Series B financing round (after completing a €44 million financing last year), including advancing two clinical trials simultaneously — one FDA IDE trial aimed at obtaining U.S. market approval, and another landmark randomized treatment trial in Europe. CorFlow's technological objective is to become the first solution capable of both diagnosing and treating microvascular obstruction (MVO) in heart disease patients through a system precisely adapted to existing interventional cardiology workflows.For specific details, see "CoFI: Intraoperative Diagnosis and Drug Delivery Platform for Microvascular Obstruction (MVO) Completes 340 Million Financing》。

Chris O’Connell's Statement

"I am honored to join the CorFlow team and am highly motivated to help address the significant unmet medical needs of patients with microvascular obstruction. With a transformative technology portfolio, a talented CEO and team, and experienced investors, CorFlow is poised for breakthrough success. We have all the elements in place to achieve extraordinary accomplishments."